Table 3 Clinical results
Patients in hemoperfusion group/control group | Day 1 (pretreatment) (n = 18) 9/9 | Day 2 (posttreatment) (n = 16) 9/7 | Day 3 (n = 15) 9/6 | Day 4 (n = 15) 9/6 | Day 5 (n = 15) 9/6 |
|---|---|---|---|---|---|
Respiratory data, mean (SD) | |||||
Pa02/Fi02 ratio | |||||
Hemoperfusion group | 260 (75) | 260 (110) | 242 (92) | 222 (61) | 251 (78) |
Control group | 209 (117) | 218 (114) | 247 (45) | 215 (37) | 185 (54) |
HC03 (mmHg) | |||||
Hemoperfusion group | 17.4 (2.8) | 22 (3) | 25.4 (4.8) | 28.6 (2.7) | 28.6 (1.6) |
Control group | 16 (4.7) | 24 (4) | 26.7 (3.6) | 28.6 (2.7) | 29.7 (0.5) |
pH | |||||
Hemoperfusion group | 7.3 (0.05) | 7.4 (0.08) | 7.4 (0.08) | 7.5 (0.04) | 7.5 (0.05) |
Control group | 7.2 (0.1)* | 7.3 (0.12) | 7.4 (0.04) | 7.4 (0.04) | 7.4 (0.06) |
Hemodynamic data, mean (SD) | |||||
MAP (mmHg) | |||||
Hemoperfusion group | 74.7 (8.4) | 76.6 (14) | 78.5 (11.2) | 80.2 (15) | 78.3 (11.7) |
Control group | 78.8 (13.4) | 83.3 (15) | 90.3 (9.5) | 87.8 (14.4) | 78.7 (10) |
Noradrenaline (µg/kg/min) | |||||
Hemoperfusion group | 0.8 (0.5) | 0.7 (0.7) | 0.5 (0.6) | 0.3 (0.7) | 0.4 (0.8) |
Control group | 1.3 (0.7) | 1.1 (1.2) | 0.3 (0.6) | 0.2 (0.4) | 0.2 (0.3) |
Dobutamine (µg/kg/min) | |||||
Hemoperfusion group | 1.5 (4.6) | 3.2 (5.4) | 3.1 (4.6) | 2 (4.5) | 2.1 (4.5) |
Control group | 0.5 (1.6) | –* | 1.6 (4) | 1.6 (4) | 0.8 (2.0) |
Central venous oxygen Saturat | |||||
Hemoperfusion group | 72 (6.5) | 62 (12) | 61,4 (5.5) | 63.5 (8.6) | 64.1 (15) |
Control group | 66 (8) | 61 (8.6) | 65.2 (7.7) | 57.3 (9.9) | 58.4 (5.3) |
Cardiac index (L/min/m2) | |||||
Hemoperfusion group | 3.3 (0.76) | 2.6 (0.6) | 3.2 (0.9) | 3.1 (0.9) | 3.8 (1.2) |
Control group | 3.3 (1.18) | 2.5 (0.6) | 2.6 (0.7) | 2.7 (0.8) | 2.5 (0.5) |
ISVR (dynes/cm−5/m2) | |||||
Hemoperfusion group | 1113.6 (430) | 1468.8 (751) | 1115.4 (420) | 1097 (522) | 1261 (699) |
Control group | 1689.9 (881) | 2745.5 (1719) | 2528.5 (585)* | 2427 (483)* | 2600 (400) |
EVLWi (ml/kg) | |||||
Hemoperfusion group | 7.5 (3) | 6.9 (2.7) | 6.3 (1.8) | 7 (2.7) | 7.5 (4) |
Control group | 7.7 (3.5) | 6.3 (1.8) | 6.1 (1.7) | 5.7 (1.9) | – |
PVPi | |||||
Hemoperfusion group | 2.1 (0.6) | 1.8 (0.7) | 1.8 (0.57) | 1.9 (0.7) | 1.75 (0.75) |
Control group | 1.6 (0.1) | 1.6 (0.2) | 1.7 (0.3) | 1.3 (0.2) | – |
GEDVi | |||||
Hemoperfusion group | 950 (380 | 965 (324) | 872 (277) | 832 (196) | 978 (408) |
Control group | 1000 (392) | 761 (348) | 1107 (532) | 809 (99) | – |
Renal data, mean (SD) | |||||
Serum creatinine (mg/dl) | |||||
Hemoperfusion group | 3.8 (2) | 2.6 (1.2) | 1.9 (0.9) | 1.6 (0.6) | 1.8 (0.8) |
Control group | 2.9 (1.3) | 1.8 (1.2) | 1.5 (0.9) | 1.5 (1) | 1.5 (0.9) |
Azotemia (mg/dl) | |||||
Hemoperfusion group | 119 (36) | 84 (33) | 67.5 (28) | 67 (28) | 79 (37) |
Control group | 106 (38) | 62 (19) | 62 (19) | 66 (30) | 82 (41) |